C. Boos

发表

Ivabradine in heart failure: what about digoxin?

S. Gorman, C. Boos, 2008, The Lancet.

Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial

Benjamin R. Szwejkowski, J. McMurray, I. Matthews, 2022, The Lancet.

The EUROPA trial

C. Boos, 2003, The Lancet.

Total knee arthroplasty infection due to Abiotrophia defectiva.

J. Gille, M. Russlies, A. Ince, 2002, Journal of medical microbiology.

Comparative study of the efficacy of fluconazole versus amphotericin B/flucytosine in surgical patients with systemic mycoses

P. Kujath, C. Boos, K. Lerch, 1993, Infection.

Anthracyclin‐Zytostatika (Doxorubicin, Epirubicin, Daunorubicin, Idarubicin) [Biomonitoring Methods in German language, 2000]

C. Boos, Grimm, 2012 .

Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial

Benjamin R. Szwejkowski, J. McMurray, I. Matthews, 2022, The Lancet.

Biophysical and biochemical alterations of renal cortical membranes in diabetic rat.

G. Kaloyanides, C. Josepovitz, L. Ramsammy, 1993, Biochimica et biophysica acta.

Oral induction of tolerance to nickel sensitization in mice.

R. Scheper, G. Kraal, I. V. van Hoogstraten, 1993, The Journal of investigative dermatology.

Back Pain in a Bangladeshi Worker in Iraq

T. Colman, S. Dickson, C. Boos, 2010, Journal of the Royal Army Medical Corps.